<?xml version="1.0" encoding="UTF-8"?>
<p>Antiviral vaccines generally fall into one of the following types: inactive or live-attenuated viruses, virus-like particle (VLP), viral vectors, protein-based, DNA-based, and mRNA-based vaccines. There are 363 patents in the CAS content collection related to vaccine development to prevent viral disorders/diseases, including SARS and MERS. Of these, 175 patents disclose vaccines for non-coronaviruses that may have relevance to SARS and MERS, while 188 patents are directly associated with anti-SARS and anti-MERS vaccines with a demonstrated immune response. Supporting Information 
 <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00272/suppl_file/oc0c00272_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">Table S2</ext-link> contains additional information on these SARS/MERS vaccine-related patents.
</p>
